What is Chimerix, Inc. (CMRX)?

Chimerix, Inc. (CMRX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CMRX?

The current price of CMRX is $8.54. Prices are updated in real time on Stocks360.

What is CMRX's price-to-earnings (PE) ratio?

CMRX's trailing twelve-month PE ratio is -8.63, based on current price and earnings per share data available on Stocks360.

What is CMRX's market capitalization?

CMRX's market capitalization is $801,084,452.00, placing it in the small-cap tier.

Chimerix, Inc. (CMRX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$8.54

Market Cap

$801.08M

PE (TTM)

-8.63

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.18

Day Range

$8.54 – $8.54

52-wk Range

$0.75 – $8.55

Avg Volume

N/A

Volume

2.55M

Chimerix, Inc. (CMRX) is a publicly traded company in the Healthcare sector. Latest price: $8.54. Market cap $801.08M. Trailing PE -8.63. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

Earnings

Most Recent

May 7, 2025

EPS $-0.25 vs est. $-0.27

Beat by $0.02

Proprietary Signals

Signal snapshot temporarily unavailable.

About Chimerix, Inc.

Chimerix, Inc. operates as a biopharmaceutical company, committed to advancing therapeutic solutions that improve the lives of individuals grappling with severe medical conditions. Its sole approved medicine is TEMBEXA (brincidofovir), a lipid conjugate designed to combat smallpox by inhibiting viral DNA synthesis, positioned as a critical medical countermeasure. Beyond its commercial offering, Chimerix boasts a robust clinical-stage pipeline: ONC201 targets recurrent diffuse midline glioma in patients whose tumors possess the H3 K27M mutation. ONC206, an imipridone, is a Phase I candidate for solid tumors, functioning as both a Dopamine Receptor D2 (DRD2) antagonist and a caseinolytic protease P (ClpP) agonist. Notably, it exhibits superior non-competitive antagonism of DRD2 compared to ONC201. ONC212, another imipridone, acts as an agonist for the orphan G protein-coupled receptor (GPCR) tumor suppressor GPR132 and ClpP. This compound is being explored for a range of solid tumors and blood cancers, including pancreatic cancer and leukemias. dociparstat sodium (DSTAT) aims to overcome chemotherapy resistance in acute myeloid leukemia (AML) by inhibiting crucial proteins found in…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-8.63×
P/S (TTM)	3778.70×
P/B	6.30×
PEG	0.81×
P/FCF (TTM)	-10.64×
EV / EBITDA	-7.99×
EV / Sales	3634.40×
Earnings Yield	-11.54%
Free Cash Flow Yield	-9.40%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$770.49M
Revenue (TTM)	$212.00K
Net Income (TTM)	-$92.43M
Free Cash Flow (TTM)	-$75.26M
Net Debt	-$30.59M
Working Capital	$112.08M
Gross Margin	100.00%
Operating Margin	-45550.47%
Net Margin	-41691.98%
Return on Equity	-56.17%
Return on Invested Capital	-79.06%